Pipeline Review for Acute Renal Failure – H1 2020 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline Review, H1 2020, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape.

Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases and chest pain. The predisposing factors include age, diabetes, high blood pressure, heart failure and kidney diseases. Treatment includes antibiotics and diuretics.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 10, 31 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

  • Introduction
  • Acute Renal Failure (ARF) (Acute Kidney Injury) – Overview
  • Acute Renal Failure (ARF) (Acute Kidney Injury) – Therapeutics Development
  • Acute Renal Failure (ARF) (Acute Kidney Injury) – Therapeutics Assessment
  • Acute Renal Failure (ARF) (Acute Kidney Injury) – Companies Involved in Therapeutics Development
  • Acute Renal Failure (ARF) (Acute Kidney Injury) – Drug Profiles
  • Acute Renal Failure (ARF) (Acute Kidney Injury) – Dormant Projects
  • Acute Renal Failure (ARF) (Acute Kidney Injury) – Discontinued Products
  • Acute Renal Failure (ARF) (Acute Kidney Injury) – Product Development Milestones
  • Appendix

Companies Mentioned

  • A1M Pharma AB
  • Alloksys Life Sciences BV
  • Am-Pharma BV
  • Angion Biomedica Corp
  • Arch Biopartners Inc
  • Atox Bio Ltd
  • Axolo Pharma Inc
  • Balmes Transplantation SAS
  • Bessor Pharma LLC
  • Cellmid Ltd
  • CFM Pharma Holding BV
  • Cypralis Ltd
  • DepYmed Inc
  • DURECT Corp
  • Evotec SE
  • Exponential Biotherapies Inc
  • F. Hoffmann-La Roche Ltd
  • GeneScience Pharmaceuticals Co Ltd
  • Kalytera Therapeutics Inc
  • Kantum Pharma Inc
  • Klotho Therapeutics Inc
  • Kringle Pharma Inc
  • Liminal BioSciences Inc
  • Mission Therapeutics Ltd
  • Mitobridge Inc
  • Mitotech SA
  • Nephraegis Therapeutics
  • Pharmicell Co Ltd
  • Pharming Group NV
  • Praetego Inc
  • Q BioMed Inc
  • Quark Pharmaceuticals Inc
  • Radikal Therapeutics Inc
  • Rediscovery Life Sciences
  • Redx Pharma Plc
  • Renibus Therapeutics Inc
  • RHEACELL GmbH & Co KG
  • Sentien Biotechnologies Inc
  • Silver Creek Pharmaceuticals Inc
  • Spherium Biomed SL
  • STATegics Inc
  • Sulfateq BV
  • TES Pharma SRL
  • TheraSource LLC
  • Theratome Bio Inc
  • Torrent Pharmaceuticals Ltd
  • Unicycive Therapeutics Inc
  • Vasomune Inc
  • vasopharm GmbH
  • Xigen SA

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ydr6u1

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900